Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €8.79 EUR
Change Today -0.08 / -0.90%
Volume 20.4K
ALQGC On Other Exchanges
EN Paris
As of 5:41 AM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

quantum genomics sas-regr (ALQGC) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/19/15 - €14.27
52 Week Low
10/15/14 - €3.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

quantum genomics sas-regr (ALQGC) Related Businessweek News

No Related Businessweek News Found

quantum genomics sas-regr (ALQGC) Details

Quantum Genomics Corp., a biopharmaceutical research company, develops treatments in the field of cardiovascular diseases. The company develops products for cardiovascular diseases, including hypertension and heart failure. It also focuses on developing a therapeutic approach based on Brain Aminopeptidase A Inhibition (BAPAI). The company is based in Paris, France.

7 Employees
Last Reported Date: 04/23/15

quantum genomics sas-regr (ALQGC) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: €234.1K
Compensation as of Fiscal Year 2013.

quantum genomics sas-regr (ALQGC) Key Developments

Quantum Genomics SA Presents at European Large & Midcap Event, Oct-07-2015

Quantum Genomics SA Presents at European Large & Midcap Event, Oct-07-2015 . Venue: Palais Brongniart, 28 Place de la Bourse, entrée Rue Vivienne, 75002 Paris, France.

Quantum Genomics Obtains Positive Results with Heart Failure Study in Dogs

Quantum Genomics announced that the study for the prevention and treatment of heart failure in dogs has been completed within the projected timeline. The results show a statistically significant improvement during the fourth week in the cardiac ejection fraction in dogs treated over a 28-day period compared to untreated dogs. It reinforces the pertinence of the development of brain aminopeptidase A inhibitors (BAPAIs), in animal and human health, for the treatment of heart failure. Quantum Genomics points out that this study in dogs was carried out as part of the collaboration agreement with licensing option signed with a major company in the field of animal health. The pharmaceutical partner now has six months to exercise the option to continue development and market the future animal health drug under a license agreement to be negotiated with Quantum Genomics.

Quantum Genomics SA Presents at Second French Life Science Days Conference, Jun-17-2015

Quantum Genomics SA Presents at Second French Life Science Days Conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALQGC:FP €8.79 EUR -0.08

ALQGC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALQGC.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALQGC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 124.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 103.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUANTUM GENOMICS SAS-REGR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at